Motor neuron diseases (MNDs) are a group of neurodegenerative disorders characterized by the selective damage of motor neurons — nerve cells responsible for transmitting impulses from the brain and spinal cord to muscles. This leads to their gradual weakness, atrophy, and loss of voluntary movements.
These diseases share a common pathogenetic mechanism — motor neuron death — but differ in the level of involvement, clinical presentation, and rate of progression.
Main Types of Motor Neuron Diseases
-
Amyotrophic Lateral Sclerosis (ALS) — the most well-known and severe form, affecting both upper and lower motor neurons. It is characterized by a combination of spasticity and muscle atrophy, fasciculations, progressive motor impairment, and loss of respiratory function.
-
Progressive Muscular Atrophy (PMA) — primarily affects lower motor neurons. It presents with marked weakness and atrophy without spasticity; progression is typically slower than in ALS.
-
Primary Lateral Sclerosis (PLS) — involves mainly upper motor neurons, causing spasticity, gait disturbances, and slurred speech. Muscle atrophy is minimal.
-
Progressive Bulbar Palsy (PBP) — degeneration of motor neurons in the medulla oblongata, leading to impaired speech, swallowing, and respiration. It may occur independently or as part of ALS.
-
Spinal Muscular Atrophy (SMA) — an inherited form associated with mutations in the SMN1 gene, leading to spinal motor neuron death and significant muscle weakness from childhood.
Pathogenesis Features
The key feature is the selective vulnerability of motor neurons while sensory and cognitive functions remain preserved in early stages.
Mechanisms of damage include:
• Genetic mutations (e.g., in SOD1, C9orf72, TARDBP, FUS) leading to impaired protein metabolism and toxic protein aggregation in neurons;
• Oxidative stress and excess free radicals damaging cellular membranes;
• Glutamate excitotoxicity — an imbalance between excitatory and inhibitory signals in neural circuits;
• Mitochondrial dysfunction and disrupted energy metabolism;
• Inflammation and autoimmune reactions within neural tissue;
• Impaired axonal transport and degradation of synaptic connections.
Factors Affecting Development and Progression
• Genetic predisposition — found in about 5–10% of ALS patients, though even sporadic cases may have genetic risk variants.
• Age — incidence increases after age 40, peaking between 55 and 65.
• Sex — males are slightly more frequently affected.
• Exposure to toxins and heavy metals, occupational risks (e.g., contact with pesticides, lead, physical exertion).
• Oxidative stress, viral infections, and immune dysregulation — also considered potential triggers.
Clinical Features
The diseases develop gradually, with progressive weakness, atrophy, and fasciculations in the limbs, speech and swallowing difficulties, and respiratory impairment.
Upper motor neuron involvement causes increased tone, hyperreflexia, and spasticity.
Depending on the form, different muscle groups are affected, but progression is relentless.
Consciousness, intellect, and sensory function are typically preserved until late stages, making the disease psychologically devastating.
Prognosis
The prognosis for most motor neuron diseases is poor.
• ALS: Average survival after diagnosis is 3–5 years, though 10–20% of patients progress slowly and survive for over 10 years.
• PMA: Progresses more slowly, with a relatively better prognosis.
• PLS: May last decades but leads to severe disability.
• SMA: Prognosis depends on type — severe childhood forms carry high infant mortality, while milder types allow survival into adulthood.
Modern Approaches Using Biobank-Derived Products
The treatment of motor neuron diseases using biobank-derived products represents one of the most rapidly evolving areas of modern neuroregenerative medicine.
Although no cellular or exosome-based therapy is yet recognized as a clinical standard for ALS or other neurodegenerative disorders, numerous studies show that biobanked cells and their derivatives (stem cells, exosomes, secretomes) can exert strong neuroprotective, anti-inflammatory, and regenerative effects.
1. Mesenchymal Stem Cells (MSCs)
Sources: Bone marrow, umbilical cord, adipose tissue, placenta — the most common biobank-derived cell types.
Mechanisms of action:
• Suppression of microglial and astrocytic activation (reducing neuroinflammation and preventing motor neuron death);
• Secretion of neurotrophic factors — BDNF, GDNF, VEGF, NGF — supporting neuronal survival and function;
• Stimulation of angiogenesis and neuroregeneration;
• Immunomodulation (decreasing IL-1β, TNF-α, IL-6; increasing TGF-β).
Efficacy:
• In clinical trials, MSC therapy in ALS patients slowed disease progression by 30–50% over 6–12 months after infusion.
• Some patients showed improved motor and respiratory function in early stages.
• Repeated administrations (every 3–6 months) provided more durable benefits.
Routes of administration: Intrathecal (into cerebrospinal fluid), intravenous, or combined.
The intrathecal route is considered most effective, as cells interact directly with affected neuronal structures.
2. Exosomes and Extracellular Vesicles Derived from MSCs
Advantages:
Contain no live cells → lower risk of immune reactions; easier to standardize and store in biobanks.
Mechanism:
• Transfer of microRNAs (miR-124, miR-133b, miR-21) that regulate neurogenesis and suppress neuronal apoptosis;
• Restoration of synaptic activity and intercellular communication;
• Stabilization of neuronal membranes and reduction of oxidative stress.
Research findings:
• MSC-derived exosomes reduced motor neuron death in ALS models and improved electrophysiological properties.
• Neuronal survival increased by 40–60% compared to controls.
Perspective:
Viewed as a safe alternative to live-cell therapy, especially for repeated use.
3. Neural Stem Cells (NSCs) and Neuronal Progenitors
Source: Fetal or induced pluripotent stem cells (iPSCs) stored in biobanks.
Goal: Partial replacement of lost motor neurons and restoration of neural circuits.
Mechanism: Differentiate into neurons, astrocytes, and oligodendrocytes — enabling remyelination and synaptic network recovery.
Clinical results:
• Early-phase ALS studies showed stabilization of motor function for 6–9 months.
• Improvements in respiratory function and muscle tone were observed without severe adverse effects.
• Outcomes appeared more stable than with other biobank-derived products.
Read more information about new treatment protocols using stem cells in motor diseases: https://mediland.clinic/2025/06/30/stem-cell-therapy-is-the-latest-therapy-option-for-multiple-sclerosis-in-2025/
4. Combined Cell-Based Products (MSC + NSC or MSC + Exosomes)
Modern biobank therapy increasingly employs combinations of mesenchymal cells and their extracellular vesicles, enhancing both anti-inflammatory and regenerative effects.
This approach ensures longer-lasting action through sustained release of neurotrophic factors.
Why Early Initiation of Biobank Therapy Is Critical
Starting treatment with biobank-derived products at an early stage of neurodegenerative disease — particularly motor neuron diseases — is crucial because this is when the nervous system retains the greatest potential for protection and recovery.
At early stages, massive neuron death has not yet occurred, and inflammatory and degenerative processes remain partially reversible.
Biobank products — such as MSCs, neural progenitors, or exosomes — act mainly through neuroprotection and immunomodulation, not replacement of lost cells.
Thus, the earlier the treatment begins, the more viable neurons can be preserved and the greater the chance of slowing disease progression.
Key reasons include:
-
Prevention of irreversible neuronal loss — neurons cannot fully regenerate; once destroyed, they are not replaced.
-
Reduction of neuroinflammation — early intervention prevents chronic inflammation and secondary neuronal damage.
-
Preservation of synaptic connections — neurotrophic factors (BDNF, GDNF, VEGF) help maintain neural plasticity.
-
Better tissue responsiveness — less damaged neural tissue responds more effectively to growth signals.
-
Higher treatment efficacy — clinical observations show 30–50% slower disease progression in early-treated patients.
-
Prevention of systemic complications — maintaining metabolic and immune stability reduces secondary effects like muscle wasting or respiratory failure.
In summary, early biobank therapy aims not merely to “treat,” but to preserve — maintaining neuronal networks, tissue plasticity, and adaptive capacity.
Once advanced degeneration develops, even the most advanced therapies can only slow, not reverse, the process.
Why Repeated Therapy Every 12–18 Months Is Recommended
Repeating biobank-derived therapy every 1–1.5 years is recommended because its biological effects are time-limited, while neurodegenerative and inflammatory processes are long-term and progressive.
A single infusion triggers a powerful regenerative and anti-inflammatory response, but over time these effects diminish as cell activity declines.
Biobank products — whether MSCs, neural progenitors, or exosomes — act primarily by secreting bioactive molecules (growth factors, cytokines, microRNAs).
Their concentration and biological impact naturally decrease over several months.
Repeat therapy serves several critical purposes:
-
Maintaining steady levels of neuroprotective and regenerative factors — each session renews the biological stimulation of tissues, ensuring continuous release of BDNF, GDNF, VEGF, IGF, and others.
-
Controlling chronic inflammation — helps stabilize immune activity and prevents fibrosis or oxidative stress.
-
Slowing disease progression — periodic “re-activation” of regenerative mechanisms delays functional decline.
-
Restoring vascular and metabolic homeostasis — repeated treatments maintain improved microcirculation and tissue nutrition.
-
Adjusting therapy to patient condition — allows dose or product composition to be fine-tuned for optimal effect.
Thus, repeated therapy every 12–18 months is not a formality but a key part of long-term neuroprotection and systemic restoration, maintaining equilibrium between degenerative and regenerative processes and extending functional stability.
Prognosis and Perspectives
While no current approach offers a complete cure, biobank-based cell therapy can significantly slow neurodegeneration, improve quality of life, and extend patients’ active years.
Greatest benefits are seen with early intervention, where disease progression can be slowed by 30–50% compared to control groups.
Life Extension
In neurodegenerative diseases (e.g., MNDs, ALS, Parkinson’s disease) and systemic degenerative conditions, biobank-derived products can slow progression by 40–60% compared with standard therapy.
Practically, this means:
• Patients starting therapy early may live 5–12 years longer than average prognoses.
• Those treated at mid-stages experience slower motor, cognitive, and autonomic decline, retaining independence longer.
The key value lies not merely in extending biological lifespan but in prolonging active life — maintaining speech, movement, breathing, and self-care abilities.
Quality of Life Improvement
Biobank-derived therapies influence multiple factors shaping well-being:
• Neuroprotection — slows neuronal death and supports nerve conductivity.
• Anti-inflammatory effect — reduces chronic inflammation, pain, and spasticity.
• Mitochondrial support — improves energy metabolism and reduces fatigue.
• Tissue trophism and microcirculation — enhances muscle and organ nourishment.
• Emotional stabilization — lessens anxiety, depression, and cognitive decline through neurotrophic effects (BDNF, GDNF, IGF-1).
These effects generally last 12–18 months and are reinforced by maintenance therapy.
Timing Is the Key Factor
The earlier the treatment begins, the higher the chances to:
• Preserve functional neurons and prevent irreversible loss;
• Activate endogenous repair mechanisms;
• Maintain disease at a compensated stage.
At early stages, biobank product efficacy can be 2–3 times higher than in late stages, when sclerosis and fibrosis are already established.
Long-Term Strategy
Biobank therapy is not a one-time intervention — it functions as long-term biological support for the body.
Repeated courses every 12–18 months help preserve results and prevent regression.
For chronic neurodegenerative conditions, this ensures sustained improvement in quality of life over many years.
Some patients’ reviews about success rate of MS stem cells treatment: https://mediland.clinic/2024/01/25/real-patients-reviews-about-stem-cells-treatment-of-multiple-sclerosis-2021-2023/
Conclusion
Biobank-derived therapies do not deliver an instant “miracle,” but with systematic and early use, they can:
• Slow disease progression by up to 60% or more;
• Extend life expectancy by 5–12 years or longer (depending on diagnosis and stage);
• Most importantly — preserve functional independence, cognitive clarity, and quality of life significantly longer than with standard treatment alone.